Literature DB >> 19525934

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

Deborah Silvera1, Rezina Arju, Farbod Darvishian, Paul H Levine, Ladan Zolfaghari, Judith Goldberg, Tsivia Hochman, Silvia C Formenti, Robert J Schneider.   

Abstract

Inflammatory breast cancer (IBC) is the most lethal form of primary breast cancer. IBC lethality derives from generation of tumour emboli, which are non-adherent cell clusters that rapidly spread by a form of continuous invasion known as passive metastasis. In most cancers, expression of E-cadherin, an epithelial marker, is indicative of low metastatic potential. In IBC, E-cadherin is overexpressed and supports formation of tumour emboli by promoting tumour cell interactions rather than adherence to stroma. E-cadherin, a surface component of adherens junctions, is anchored by interaction with p120 catenin (p120). We show that the unique pathogenic properties of IBC result in part from overexpression of the translation initiation factor eIF4GI in most IBCs. eIF4GI reprograms the protein synthetic machinery for increased translation of mRNAs with internal ribosome entry sites (IRESs) that promote IBC tumour cell survival and formation of tumour emboli. Overexpression of eIF4GI promotes formation of IBC tumour emboli by enhancing translation of IRES-containing p120 mRNAs. These findings provide a new understanding of translational control in the development of advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525934     DOI: 10.1038/ncb1900

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  32 in total

1.  Persistent E-cadherin expression in inflammatory breast cancer.

Authors:  C G Kleer; K L van Golen; T Braun; S D Merajver
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

2.  Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma.

Authors:  Mary L Alpaugh; James S Tomlinson; Sina Kasraeian; Sanford H Barsky
Journal:  Oncogene       Date:  2002-05-16       Impact factor: 9.867

3.  Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung.

Authors:  I B Rosenwald; M J Hutzler; S Wang; L Savas; A E Fraire
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

4.  A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.

Authors:  Derek R McClusky; Quyen Chu; Herbert Yu; Arrigo Debenedetti; Lester W Johnson; Carol Meschonat; Richard Turnage; John C McDonald; Fleurette Abreo; Benjamin D L Li
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

5.  A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.

Authors:  Steve Braunstein; Ksenia Karpisheva; Carolina Pola; Judith Goldberg; Tsivia Hochman; Herman Yee; Joan Cangiarella; Rezina Arju; Silvia C Formenti; Robert J Schneider
Journal:  Mol Cell       Date:  2007-11-09       Impact factor: 17.970

6.  Description of a spheroid model for the study of radiation and chemotherapy effects on hypoxic tumor cell populations.

Authors:  D H Moore; M B Rouse; G S Massenburg; E M Zeman
Journal:  Gynecol Oncol       Date:  1992-10       Impact factor: 5.482

7.  Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms.

Authors:  A Keirsebilck; S Bonné; K Staes; J van Hengel; F Nollet; A Reynolds; F van Roy
Journal:  Genomics       Date:  1998-06-01       Impact factor: 5.736

Review 8.  Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype.

Authors:  Yun Gong
Journal:  Semin Oncol       Date:  2008-02       Impact factor: 4.929

9.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.

Authors:  C G Colpaert; P B Vermeulen; I Benoy; A Soubry; F van Roy; P van Beest; G Goovaerts; L Y Dirix; P van Dam; S B Fox; A L Harris; E A van Marck
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

Review 10.  Update on inflammatory breast cancer.

Authors:  Florence Lerebours; Ivan Bieche; Rosette Lidereau
Journal:  Breast Cancer Res       Date:  2005-01-20       Impact factor: 6.466

View more
  116 in total

1.  Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.

Authors:  Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Tse K Yu; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Melissa L Bondy; Wei Yang; Jie S Willey; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz
Journal:  Oncologist       Date:  2011-12-06

2.  Identification of differential translation in genome wide studies.

Authors:  Ola Larsson; Nahum Sonenberg; Robert Nadon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

Review 3.  The Untranslated Regions of mRNAs in Cancer.

Authors:  Samantha L Schuster; Andrew C Hsieh
Journal:  Trends Cancer       Date:  2019-03-22

4.  eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress.

Authors:  Elena Bevilacqua; Xinglong Wang; Mithu Majumder; Francesca Gaccioli; Celvie L Yuan; Chuanping Wang; Xiongwei Zhu; Lindsay E Jordan; Donalyn Scheuner; Randal J Kaufman; Antonis E Koromilas; Martin D Snider; Martin Holcik; Maria Hatzoglou
Journal:  J Biol Chem       Date:  2010-03-25       Impact factor: 5.157

Review 5.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

Review 6.  Role of translation initiation factor 4G in lifespan regulation and age-related health.

Authors:  Amber Howard; Aric N Rogers
Journal:  Ageing Res Rev       Date:  2014-01-03       Impact factor: 10.895

7.  TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.

Authors:  Xiaoping Wang; Hitomi Saso; Takayuki Iwamoto; Weiya Xia; Yun Gong; Lajos Pusztai; Wendy A Woodward; James M Reuben; Steven L Warner; David J Bearss; Gabriel N Hortobagyi; Mien-Chie Hung; Naoto T Ueno
Journal:  Cancer Res       Date:  2013-09-06       Impact factor: 12.701

8.  The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G.

Authors:  Columba de la Parra; Elisa Otero-Franqui; Michelle Martinez-Montemayor; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

9.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

10.  Tumor-associated and disease-associated autoantibody repertoires in healthy colostrum and maternal and newborn cord sera.

Authors:  Asaf Madi; Sharron Bransburg-Zabary; Ayala Maayan-Metzger; Gittit Dar; Eshel Ben-Jacob; Irun R Cohen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.